THYQUIDITY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THYQUIDITY (THYQUIDITY).
Thyroid hormone replacement; levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, regulating gene transcription and increasing metabolic rate.
| Metabolism | Hepatic and renal metabolism; glucuronidation and sulfation; deiodination via deiodinases. |
| Excretion | Thyquidity (levothyroxine sodium) is primarily excreted via the kidneys as unchanged drug and metabolites. Approximately 20-40% of an oral dose is excreted in feces via biliary elimination, with the remainder eliminated renally. Up to 80% of an administered dose appears in urine as thyroxine and its metabolites, primarily glucuronide and sulfate conjugates. |
| Half-life | The terminal elimination half-life of levothyroxine is approximately 6-7 days in euthyroid individuals. In hyperthyroidism, half-life decreases to 3-4 days; in hypothyroidism, it can extend to 9-10 days. This long half-life supports once-daily dosing and allows for steady-state achievement in about 6-8 weeks. |
| Protein binding | Levothyroxine is extensively bound to plasma proteins, primarily thyroxine-binding globulin (TBG) (~75%), with additional binding to transthyretin (thyroxine-binding prealbumin, TBPA) (~15%) and albumin (~10%). Total protein binding is >99%. |
| Volume of Distribution | The apparent volume of distribution (Vd) of levothyroxine is approximately 0.10-0.15 L/kg in euthyroid individuals. This relatively low Vd reflects its high protein binding and limited tissue distribution. In hypothyroidism, Vd may decrease due to reduced tissue metabolism. |
| Bioavailability | Oral levothyroxine has a bioavailability of approximately 40-80%, with significant inter-individual variation depending on gastrointestinal factors and food interactions. The brand-name Thyquidity (oral solution) may have slightly higher and more consistent absorption compared to tablets; however, the manufacturer reports bioavailability equivalent to tablet formulations when taken consistently. |
| Onset of Action | For oral administration, clinical improvement in hypothyroid symptoms begins within 3-5 days, with full therapeutic effect typically reached by 6-8 weeks. Intravenous levothyroxine (for myxedema coma) shows a faster onset, with improvement in mental status and vital signs observed within 6-12 hours. |
| Duration of Action | The duration of action of levothyroxine is approximately 2-3 weeks after a single oral dose, correlating with its long half-life. For chronic therapy, daily dosing maintains stable serum thyroid hormone levels. In myxedema coma, IV doses require adjustment every 24-48 hours based on clinical response. |
50 mg orally once daily, with or without food.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-60 mL/min: 25 mg once daily; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: 25 mg once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Weight <40 kg: 1.5 mg/kg orally once daily; Weight ≥40 kg: 50 mg once daily. |
| Geriatric use | No specific adjustment; monitor renal function and consider starting at 25 mg once daily in patients >75 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for THYQUIDITY (THYQUIDITY).
| Breastfeeding | Levothyroxine is excreted into breast milk in minimal amounts (M/P ratio < 0.1). Not expected to cause adverse effects in breastfed infants at maternal therapeutic doses. Monitoring of infant thyroid function is not routinely required. |
| Teratogenic Risk | THYQUIDITY (levothyroxine) is pregnancy category A. No increased risk of fetal malformations when used at recommended doses. Thyroid hormone is critical for fetal neurodevelopment; maternal hypothyroidism increases risks of miscarriage, preterm delivery, and low IQ. |
■ FDA Black Box Warning
Not indicated for treatment of obesity or weight loss; ineffective and dangerous at supratherapeutic doses.
| Serious Effects |
Untreated thyrotoxicosis, acute myocardial infarction, uncorrected adrenal insufficiency.
| Precautions | Cardiac toxicity with over-replacement; monitor TSH levels; use cautiously in cardiovascular disease, diabetes insipidus, and adrenal insufficiency. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal TSH every 4-6 weeks during pregnancy, and 4 weeks post-dose adjustment. Aim for trimester-specific TSH targets: first trimester 0.2-2.5 mIU/L, second 0.3-3.0, third 0.3-3.0. Fetal surveillance includes ultrasound for growth and well-being if indicated. |
| Fertility Effects | Adequate levothyroxine therapy restores euthyroidism and can improve fertility in women with hypothyroidism. Untreated hypothyroidism may cause anovulation or luteal phase defects. No direct adverse effects on fertility. |